Roflumilast is an inhibitor of phosphodiesterase-4 (PDE4) and can suppress the hydrolysis of cAMP in inflammatory cells, conferring anti-inflammatory effects. This study aimed to investigate the protective effects of roflumilast on hyperoxia-induced acute lung injury (HALI) in a rat model. Male Sprague-Dawley rats were randomly assigned into: control group; HALI group; 2.5 mg/kg roflumilast group; and 5 mg/kg roflumilast group. Rats were pressurized to 250 kPa with pure oxygen to induce lung injury. In the roflumilast groups, rats were orally administered with roflumilast at 2.5 or 5 mg/kg once before hyperoxia exposure and once daily for two days after exposure. Rats were sacrificed 72 hours after hyperoxia exposure. The lung tissues were collected for the detection of lung water content, inflammatory cytokines and NF-κB/p-NF-κB protein expression, and the bronchoalveolar lavage fluid was harvested for the measurement of protein concentration and lactate dehydrogenase activity. Results showed roflumilast at different doses could significantly reduce lung edema, improve lung pathology and reduce the expression of inflammatory cytokines in the lung. The protective effects seemed to be related to the dose of roflumilast. Our study indicates roflumilast has the potential as a medication for the treatment of HALI.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.22462/04.06.2020.3 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Right Ventricular Injury Definition and Management in Veno-Venous Extracorporeal Membrane Oxygenation.
ASAIO J
January 2025
From the Department of Critical Care Medicine, Respiratory Institute, Cleveland Clinic, Cleveland, Ohio.
Right ventricular injury (RVI) in respiratory failure receiving veno-venous extracorporeal membrane oxygenation (VV ECMO) is associated with significant mortality. A scoping review is necessary to map the current literature and guide future research regarding the definition and management of RVI in patients receiving VV ECMO. We searched for relevant publications on RVI in patients receiving VV ECMO in Medline, EMBASE, and Web of Science.
View Article and Find Full Text PDFOptimal CPAP Weaning Approaches: A Scoping Review.
J Perinat Neonatal Nurs
October 2024
Author Affiliations:Duke University School of Nursing, Durham (Ms Adeku, Mrs Defore, Dr Newberry, and Ms Yates); University of North Carolina Neonatology, Chapel Hill (Dr Newberry); and Duke University Neonatology, Durham, North Carolina (Ms Yates).
Background: Bronchopulmonary dysplasia (BPD) is a prevalent chronic lung disease affecting premature infants, leading to long-term respiratory complications, hospital readmissions, and significant financial burden on families and the health care system. BPD is caused by lung injury, making it crucial to focus on methods to minimize lung injury and prevent the transition from respiratory distress syndrome to BPD by following evidence-based respiratory support strategies.
Purpose: This scoping review examines methods for weaning preterm infants off continuous positive airway pressure (CPAP) and evaluates their effectiveness in maintaining respiratory independence.
Covert Vascular Brain Injury and Cognitive Dysfunction Among Chinese Adults Living in Canada and China: The CAHHM and PURE-MIND Studies.
Neurology
February 2025
Department of Medicine, University of Toronto, Canada.
Background And Objective: It is unclear whether variation in covert cerebrovascular disease prevalence is attributable to ethnic differences or to other factors. We aimed to examine the associations of country of residence with covert vascular brain injury (VBI) and cognitive dysfunction among Chinese adults residing in Canada and China.
Methods: This was a multisite cross-sectional study of Chinese adults aged 40-80 years in the Canadian Alliance for Healthy Hearts and Healthy Minds (CAHHM; January 1, 2014, to December 31, 2018) and Prospective Urban Rural Epidemiological-Mind (PURE-MIND; November 1, 2010, to July 31, 2015) cohorts living in Canada and China.
Efficacy of pulmonary surfactant with budesonide in premature infants: A systematic review and meta-analysis.
PLoS One
January 2025
Department of Pharmacology, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.
Pulmonary surfactant (PS) is one of the main treatment for neonates with respiratory distress syndrome (RDS). Budesonide has recently been studied as an additional treatment in such cases, but there is limited evidence supporting this. This study was implemented to determine the efficacy of PS combined with budesonide in premature infants.
View Article and Find Full Text PDFMesenchymal stem cell-derived exosomes improved septic lung injury by reducing excessive NETs formation and alleviating inflammatory response.
Allergol Immunopathol (Madr)
January 2025
Department of Pediatrics, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zheiiang, China.
To illustrate the potential of mesenchymal stem cell-derived exosomes (MSC-Exos) in mitigating septic lung injury by reducing the excessive formation of neutrophil extracellular traps (NETs), a mouse model of septic lung injury was induced through cecal ligation and puncture (CLP). The mice received intraperitoneal injections of MSC-Exos. Post injection, pathological alterations of the lung tissue were evaluated through HE staining, and the levels of inflammatory markers in each mouse group at various time points were assessed using ELISA kits.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!